Health Condition 1: L700- Acne vulgaris
Conditions
Interventions
Intervention1: Tablet Montelukast 10mg: patients will receive Montelukast 10mg daily
Follow up will done at 4 weeks, 8 weeks and 12 weeks, GAGS Score will be conducted at each follow up to assess the
Sponsors
Teerthanker Mahaveer Medical College and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: Patients with moderate acne vulgaris attending DVL OPD at TMU Hospital will be enrolled in this study. Patients of age groups 15-40 years of both sexes. Patient giving informed and written consent.
Exclusion criteria
Exclusion criteria: Patients using other systemic antibiotics in the month prior to the study. History of use of Isotretinoin therapy within past 3 months History of use of Topical antibiotics, Retinoids, Steroids in the last 2 weeks. Hypersensitivity to either of the drugs of the study. Those using drugs that interact with Doxycycline or Montelukast. All pregnant and lactating females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the safety and efficacy of Doxycycline and Montelukast in the treatment of moderate acne vulgaris. Timepoint: 4, 8, 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the safety and efficacy of Doxycycline in the treatment of moderate acne vulgaris. To determine the safety and efficacy of Montelukast in the treatment of moderate acne vulgaris. Timepoint: 4, 8, 12 weeks | — |
Countries
India
Contacts
Public ContactDr Parvathi CN
Teerthanker Mahaveer Medical College and Research Centre
Outcome results
None listed